Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein

Biochemical and Biophysical Research Communications

Volumn 355, Issue 1, 2007, Pages 136-142

  Kim, Yong Kee ^a   Song, Yong Jin ^a   Seo, Dong Wan ^b   Kang, Dong Won ^a   Lee, Hoi Young ^c   Rhee, Dong Kwon ^d   Han, Jeung Whan ^d   Ahn, Chan Mug ^e   Lee, Seokjoon ^a   Kim, Su Nam ^f  

^a Catholic Kwandong University   (South Korea)

^b Kangwon National University   (South Korea)

^c Konyang University   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Yonsei University Wonju College of Medicine   (South Korea)

^f Korea Institute of Science and Technology   (South Korea)

Author keywords

4 Chloro N (3 ((E) 3 (4 hydroxy 3 methoxyphenyl)acryloyl)phenyl)benzamide; Curcumin; Multidrug resistance; P glycoprotein

Indexed keywords

4 CHLORO N (3 (3 (4 HYDROXY 3 METHOXYPHENYL)ACRYLOYL)PHENYL)BENZAMIDE; CURCUMIN; GLYCOPROTEIN P; PACLITAXEL; RHODAMINE 123; RNA; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CHEMICAL STRUCTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; GUAIACOL; P-GLYCOPROTEIN;

EID: 33847017659     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.01.117     Document Type: Article

References (26)

1. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398
3. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58 (1989) 137-171
4. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
5. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40 Suppl. (1997) S3-S8
6. Tsuruo T., Iida H., Tsukagoshi S., and Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41 (1981) 1967-1972
7. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., and Starling J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56 (1996) 4171-4179
8. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., Binkley S.N., Kuhfeld M.T., Starling J.J., and Wrighton S.A. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290 (1999) 854-862
9. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., and Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61 (2001) 749-758
10. Roe M., Folkes A., Ashworth P., Brumwell J., Chima L., Hunjan S., Pretswell I., Dangerfield W., Ryder H., and Charlton P. Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett. 9 (1999) 595-600
11. Starling J.J., Shepard R.L., Cao J., Law K.L., Norman B.H., Kroin J.S., Ehlhardt W.J., Baughman T.M., Winter M.A., Bell M.G., Shih C., Gruber J., Elmquist W.F., and Dantzig A.H. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv. Enzyme Regul. 37 (1997) 335-347
12. van Zuylen L., Nooter K., Sparreboom A., and Verweij J. Development of multidrug-resistance convertors: sense or nonsense?. Invest. New Drugs 18 (2000) 205-220
13. Sikic B.I. Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park) 13 (1999) 183-187
14. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12 (2000) 450-458
15. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10 (2003) 159-165
16. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
17. Singh S., and Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem. 6 (2006) 259-270
18. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3 (2003) 768-780
19. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P.N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64 (2002) 573-582
20. Chearwae W., Anuchapreeda S., Nandigama K., Ambudkar S.V., and Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem. Pharmacol. 68 (2004) 2043-2052
21. Limtrakul P., Anuchapreeda S., and Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4 (2004) 13
22. Kim S.W., Kwon H.Y., Chi D.W., Shim J.H., Park J.D., Lee Y.H., Pyo S., and Rhee D.K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol. 65 (2003) 75-82
23. Woo H.B., Shin W.S., Lee S., and Ahn C.M. Synthesis of novel curcumin mimics with asymmetrical units and their anti-angiogenic activity. Bioorg. Med. Chem. Lett. 15 (2005) 3782-3786
24. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
25. Manfredi J.J., Parness J., and Horwitz S.B. Taxol binds to cellular microtubules. J. Cell Biol. 94 (1982) 688-696
26. Parness J., and Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91 (1981) 479-487